Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 21870878)

1.

Inhalation by design: novel tertiary amine muscarinic M₃ receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease.

Glossop PA, Watson CA, Price DA, Bunnage ME, Middleton DS, Wood A, James K, Roberts D, Strang RS, Yeadon M, Perros-Huguet C, Clarke NP, Trevethick MA, Machin I, Stuart EF, Evans SM, Harrison AC, Fairman DA, Agoram B, Burrows JL, Feeder N, Fulton CK, Dillon BR, Entwistle DA, Spence FJ.

J Med Chem. 2011 Oct 13;54(19):6888-904. doi: 10.1021/jm200884j. Epub 2011 Sep 20.

PMID:
21870878
2.

Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup.

Glossop PA, Lane CA, Price DA, Bunnage ME, Lewthwaite RA, James K, Brown AD, Yeadon M, Perros-Huguet C, Trevethick MA, Clarke NP, Webster R, Jones RM, Burrows JL, Feeder N, Taylor SC, Spence FJ.

J Med Chem. 2010 Sep 23;53(18):6640-52. doi: 10.1021/jm1005989.

PMID:
20804199
3.

Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 2).

Peretto I, Fossati C, Giardina GA, Giardini A, Guala M, La Porta E, Petrillo P, Radaelli S, Radice L, Raveglia LF, Santoro E, Scudellaro R, Scarpitta F, Cerri A, Menegon S, Dondio GM, Rizzi A, Armani E, Amari G, Civelli M, Villetti G, Patacchini R, Bergamaschi M, Bassani F, Delcanale M, Imbimbo BP.

J Med Chem. 2007 Apr 5;50(7):1693-7. Epub 2007 Mar 13.

PMID:
17352463
4.

Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide).

Prat M, Fernández D, Buil MA, Crespo MI, Casals G, Ferrer M, Tort L, Castro J, Monleón JM, Gavaldà A, Miralpeix M, Ramos I, Doménech T, Vilella D, Antón F, Huerta JM, Espinosa S, López M, Sentellas S, González M, Albertí J, Segarra V, Cárdenas A, Beleta J, Ryder H.

J Med Chem. 2009 Aug 27;52(16):5076-92. doi: 10.1021/jm900132z.

PMID:
19653626
5.

Discovery of novel 1-azoniabicyclo[2.2.2]octane muscarinic acetylcholine receptor antagonists.

Lainé DI, McCleland B, Thomas S, Neipp C, Underwood B, Dufour J, Widdowson KL, Palovich MR, Blaney FE, Foley JJ, Webb EF, Luttmann MA, Burman M, Belmonte K, Salmon M.

J Med Chem. 2009 Apr 23;52(8):2493-505. doi: 10.1021/jm801601v.

PMID:
19317446
6.

Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M3 receptor antagonist.

Villetti G, Pastore F, Bergamaschi M, Bassani F, Bolzoni PT, Battipaglia L, Amari G, Rizzi A, Delcanale M, Volta R, Cenacchi V, Cacciani F, Zaniboni M, Berti F, Rossoni G, Harrison S, Petrillo P, Santoro E, Scudellaro R, Mannini F, Geppetti PA, Razzetti R, Patacchini R, Civelli M.

J Pharmacol Exp Ther. 2010 Dec;335(3):622-35. doi: 10.1124/jpet.110.170035. Epub 2010 Aug 30.

7.

The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium.

Sykes DA, Dowling MR, Leighton-Davies J, Kent TC, Fawcett L, Renard E, Trifilieff A, Charlton SJ.

J Pharmacol Exp Ther. 2012 Nov;343(2):520-8. doi: 10.1124/jpet.112.194456. Epub 2012 Aug 1.

8.

Efficient conversion of a nonselective norepinephrin reuptake inhibitor into a dual muscarinic antagonist-β₂-agonist for the treatment of chronic obstructive pulmonary disease.

Osborne R, Clarke N, Glossop P, Kenyon A, Liu H, Patel S, Summerhill S, Jones LH.

J Med Chem. 2011 Oct 13;54(19):6998-7002. doi: 10.1021/jm2007535. Epub 2011 Sep 2.

PMID:
21863888
9.

Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 1).

Peretto I, Forlani R, Fossati C, Giardina GA, Giardini A, Guala M, La Porta E, Petrillo P, Radaelli S, Radice L, Raveglia LF, Santoro E, Scudellaro R, Scarpitta F, Bigogno C, Misiano P, Dondio GM, Rizzi A, Armani E, Amari G, Civelli M, Villetti G, Patacchini R, Bergamaschi M, Delcanale M, Salcedo C, Fernández AG, Imbimbo BP.

J Med Chem. 2007 Apr 5;50(7):1571-83. Epub 2007 Mar 13.

PMID:
17352462
10.

Characterization of bencycloquidium bromide, a novel muscarinic M(3) receptor antagonist in guinea pig airways.

Jiang JX, Cao R, Deng WD, Jin F, Dong XW, Zhu Y, Chen XP, Xie YC, Bao MJ, Li FF, Xie QM.

Eur J Pharmacol. 2011 Mar 25;655(1-3):74-82. doi: 10.1016/j.ejphar.2011.01.017. Epub 2011 Jan 24.

PMID:
21272572
11.

Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease.

Millan DS, Bunnage ME, Burrows JL, Butcher KJ, Dodd PG, Evans TJ, Fairman DA, Hughes SJ, Kilty IC, Lemaitre A, Lewthwaite RA, Mahnke A, Mathias JP, Philip J, Smith RT, Stefaniak MH, Yeadon M, Phillips C.

J Med Chem. 2011 Nov 24;54(22):7797-814. doi: 10.1021/jm200677b. Epub 2011 Oct 28.

PMID:
21888439
12.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
13.

Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β2-adrenoceptor agonist properties.

Hegde SS, Hughes AD, Chen Y, Steinfeld T, Jasper JR, Lee TW, McNamara A, Martin WJ, Pulido-Rios MT, Mammen M.

J Pharmacol Exp Ther. 2014 Oct;351(1):190-9. doi: 10.1124/jpet.114.216861. Epub 2014 Aug 6.

PMID:
25100753
14.

Bronchodilatory effects of S-isopetasin, an antimuscarinic sesquiterpene of Petasites formosanus, on obstructive airway hyperresponsiveness.

Lin LH, Huang TJ, Wang SH, Lin YL, Wu SN, Ko WC.

Eur J Pharmacol. 2008 Apr 28;584(2-3):398-404. doi: 10.1016/j.ejphar.2008.02.034. Epub 2008 Feb 19.

PMID:
18348887
15.

Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile.

Gavaldà A, Miralpeix M, Ramos I, Otal R, Carreño C, Viñals M, Doménech T, Carcasona C, Reyes B, Vilella D, Gras J, Cortijo J, Morcillo E, Llenas J, Ryder H, Beleta J.

J Pharmacol Exp Ther. 2009 Nov;331(2):740-51. doi: 10.1124/jpet.109.151639. Epub 2009 Aug 26.

16.

A potent, long-acting, orally active (2R)-2-[(1R)-3, 3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: novel muscarinic M(3) receptor antagonist with high selectivity for M(3) over M(2) receptors.

Mitsuya M, Kobayashi K, Kawakami K, Satoh A, Ogino Y, Kakikawa T, Ohtake N, Kimura T, Hirose H, Sato A, Numazawa T, Hasegawa T, Noguchi K, Mase T.

J Med Chem. 2000 Dec 28;43(26):5017-29.

PMID:
11150173
17.

Design, synthesis, and structure-activity relationship of tropane muscarinic acetylcholine receptor antagonists.

Lainé DI, Wan Z, Yan H, Zhu C, Xie H, Fu W, Busch-Petersen J, Neipp C, Davis R, Widdowson KL, Blaney FE, Foley J, Bacon AM, Webb EF, Luttmann MA, Burman M, Sarau HM, Salmon M, Palovich MR, Belmonte K.

J Med Chem. 2009 Aug 27;52(16):5241-52. doi: 10.1021/jm900736e.

PMID:
19630384
18.

1,4-dioxane, a suitable scaffold for the development of novel M₃ muscarinic receptor antagonists.

Del Bello F, Barocelli E, Bertoni S, Bonifazi A, Camalli M, Campi G, Giannella M, Matucci R, Nesi M, Pigini M, Quaglia W, Piergentili A.

J Med Chem. 2012 Feb 23;55(4):1783-7. doi: 10.1021/jm2013216. Epub 2012 Feb 2.

PMID:
22243489
19.

Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease.

ZuWallack AR, ZuWallack RL.

Expert Opin Pharmacother. 2004 Aug;5(8):1827-35. Review. Erratum in: Expert Opin Pharmacother. 2004 Sep;5(9):2051.

PMID:
15264997
20.

Role of muscarinic M2 and M3 receptors in guinea-pig trachea: effects of receptor alkylation.

Watson N, Reddy H, Eglen RM.

Eur J Pharmacol. 1995 May 24;278(3):195-201.

PMID:
7589155
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk